When the APP-IP sequence was added to the N terminus of the catalytic domain of MMP-2, the activity of the protease was intramolecularly inhibited. We speculate that the direction of interaction makes the active site-bound APP-IP resistant to cleavage, thereby supporting the inhibitory action of the peptide inhibitor.
Matrix metalloproteinases (MMPs)2 are a family of zincdependent endopeptidases that degrade components of the extracellular matrix (ECM) and are believed to play pivotal roles in tissue remodeling under physiological and pathological conditions such as morphogenesis, angiogenesis, tissue repair, and tumor invasion (1, 2). The association of MMPs with cancer cell invasion and metastasis has suggested that these proteases represent attractive targets for the development of novel anti-tumor therapies. However, to date, no MMP inhibitor has been developed successfully as anti-tumor drugs mainly because of deleterious side effects. Recently, inhibition of some MMPs is considered to have protumorigenic effects (3). These effects may also partially account for the failure of the inhibitors in clinical trials. In both cases, the broad specificity of the MMP inhibitors must be a stiff obstacle for developing safe and effective drugs. Most MMPs are secreted as proMMP, an inactive zymogen that has an autoinhibitory propeptide in its N terminus and is proteolytically activated by serine proteases or some activated MMPs. The activities of activated MMPs are regulated by a family of inhibitors known as tissue inhibitors of metalloproteinases (TIMPs). These physiological inhibitors also have broad specificity against MMPs; the activities of almost all MMPs are susceptible to TIMP (TIMP-1 to TIMP-4) inhibition, and some members of a disintegrin and a metalloproteinase family are also inhibited by these inhibitors (4 -6). To develop drugs for the treatment of diseases in which MMPs are involved, many hydroxamate-based inhibitors or other synthetic MMP inhibitors have been designed (7-10). Unfortunately, none of them is a specific inhibitor for individual MMPs. A common architecture of catalytic sites of MMPs probably relates to the broad specificity of the inhibitors.Among the MMP family, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are critical in the invasion of tumor cells across basement membranes, because of their strong activity against type IV collagen, a major component of basement membranes (11-13). Although they have a common substrate, MMP-2 is categorized as a good target for antican-* This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. □ S The on-line version of this article (available at http://www.jbc.org) contains supplemental data, Fig. S1, and Tables SI and SII